Martin Freed, M.D.
Martin Freed, M.D., joined the Dicerna board of directors in 2016. Dr. Freed has served as an independent consultant to several private pharmaceutical, biotechnology, and healthcare companies since 2015 and specializes in clinical and general pharmaceutical development and clinical and regulatory strategy.
Dr. Freed co-founded Civitas Therapeutics, Inc. and served as its Chief Medical Officer for four years. After Acorda Therapeutics acquired the company, he served as Senior Vice President, Clinical Development.
In addition, Dr. Freed was Chief Medical Officer for Adnexus Therapeutics, Inc. (acquired by Bristol-Myers Squibb) and Vitae Pharmaceuticals, Inc. He also was a consultant working as an acting Chief Medical Officer for Avila Therapeutics, Inc. and Taligen Therapeutics. Across these roles, he provided strategic, operational, and medical leadership for clinical pharmacology, development strategy, and preclinical development.
Dr. Freed spent nearly 14 years at GlaxoSmithKline and its predecessor, SmithKline Beecham Pharmaceuticals, where he served in numerous roles, including vice president, clinical development and medical affairs in the metabolism therapeutic area. He has authored more than 100 publications and presentations.
Dr. Freed is board-certified in internal medicine, nephrology, and clinical pharmacology. He performed his internal medicine residency at Temple University Hospital in Philadelphia and his nephrology fellowship at Yale-New Haven Hospital in Connecticut. A fellow of the American College of Physicians, Dr. Freed received his B.S. with distinction in biology from the University of Delaware and his M.D. from Pennsylvania State University’s College of Medicine.